pyrroles has been researched along with mk-1775 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, A; Dinavahi, SS; Drabick, JJ; Gowda, R; Neves, RI; Noory, MA; Robertson, GP | 1 |
| Belinsky, MG; D'Souza, J; DeMatteo, R; Devarajan, K; Duncan, JS; Einarson, MB; Heinrich, MC; Johnson, KJ; Klug, L; Kozinova, M; Litwin, S; Rink, L; Sharipova, D; von Mehren, M; Ye, S; Zhou, Y | 1 |
2 other study(ies) available for pyrroles and mk-1775
| Article | Year |
|---|---|
Moving Synergistically Acting Drug Combinations to the Clinic by Comparing Sequential versus Simultaneous Drug Administrations.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Administration Schedule; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Mice; Multiple Myeloma; Pyrazoles; Pyrimidines; Pyrimidinones; Pyrroles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Male; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrimidinones; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Triazines; Xenograft Model Antitumor Assays | 2021 |